All In Biotech

Drug Trial Radar · NCT01980888

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia

Last checked: Nov 19, 2026Latest source record: Nov 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 311 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

311

Actual

Start

Feb 5, 2014

Primary completion

May 30, 2016

Study completion Jun 16, 2016

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the progression-free survival in participants with previously untreated chronic lymphocytic leukemia (CLL) who would otherwise be suitable for bendamustine and rituximab treatment as standard of care. An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • IdelalisibDrug

    150 mg tablet administered orally twice daily

  • BendamustineDrug

    Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.

  • RituximabDrug

    Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions

  • PlaceboDrug

    Placebo to match idelalisib administered orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free SurvivalTime frame: Up to 22 months

Locations

91 sites in 13 countries. Site status is shown where the registry gives one.

  • St. Jude Heritage Healthcare Virginia K. Crosson Cancer Center

    Fullerton, California

  • UCSD Moores Cancer Center

    La Jolla, California

  • Central Coast Medical Oncology

    Santa Maria, California

  • Georgetown University

    Washington D.C., District of Columbia

  • Memorial Healthcare System

    Hollywood, Florida

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Florida Cancer Specialists-South

    Sarasota, Florida

  • Franciscan Physician Network Oncology & Hematology

    Indianapolis, Indiana

  • Siouxland Hematology-Oncology Associates, LLP

    Sioux City, Iowa

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Hematology /Oncology Associates of Northern New Jersey

    Morristown, New Jersey

  • Columbia University Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • Sarah Cannon Research Institute

    Cincinnati, Ohio

  • Signal Point Clinical Research Center

    Middletown, Ohio

  • Saint Francis Hospital

    Greenville, South Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology-Austin Midtown

    Austin, Texas

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • St Vincent's Hospital, Sydney

    Darlinghurst, New South Wales, Australia

  • Jarrett Street Specialist Centre

    North Gosford, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Flinders Medical Centre, Department of Haematology, Level 6

    Bedford Park, South Australia, Australia

  • Ashford Cancer Centre Research

    Kurralta Park, South Australia, Australia

  • Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Frankston Hospital

    Frankston, Victoria, Australia

  • Barwon Health, University Hospital Geelong

    Geelong, Victoria, Australia

  • Z N A Stuivenberg

    Antwerp, Belgium

  • AZ Sint-Jan AV Brugge-Oostende

    Bruges, Belgium

  • University Hospital Leuven

    Leuven, Belgium

  • Cancercare Manitoba - Maccharles Unit

    Winnipeg, Manitoba, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Hôpital du Sacré-Coeur de Montréal

    Montreal, Quebec, Canada

  • CHU de Québec - Hôpital de l'Enfant-Jésus

    Québec, Quebec, Canada

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.